



PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)

1/3



Ref: PDL:SCY:FEBRUARY:2010-2011/25

Dated: February 1, 2011

The National Stock Exchange of India Limited,
"Exchange Plaza",
Bandra-Kurla Complex,
Bandra (East),
Mumbai (Maharashtra).

Dear Sir/Madam,


**SUBJECT : SUBMISSION OF UNAUDITED FINANCIAL RESULTS FOR THE
QUARTER ENDED ON 31st DECEMBER, 2010**

Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copy of the Unaudited Financial Results of the Company for the quarter ended on 31th December 2010 approved by the Board of Directors in its Meeting held on 1st Day of February, 2011.

You are requested to display the same on the Notice Board of your Exchange for the information of members and general public.

Thanking you,

Yours faithfully,
For Parabolic Drugs Limited,


(Anil Kumar)
Company Secretary

Enclosed: As Above.

Regd. Office : S.C.O. 99 - 100, 3rd & 4th Floor, Sector 17 - B,
Chandigarh - 160 017 (India)
Tel. : +91-172-3914646, 3914647 Fax : +91-172-3914645

Corp. Office : 9 AB, Taimoor Nagar, New Friends Colony,
New Delhi (India)
Tel. : +91-11-64510543, 26332660

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India
Telefax : (01762) 280305

Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India
Tel. : +91-172-2591443

R & D Centre : 280-281, HSIIDC, Tehsil Barwala,
District Panchkula (Hry.) India Tel. : +91-1733-256380

website : www.parabolicdrugs.com

UNAUDITED FINANCIAL RESULTS FOR QUARTER/NINE MONTHS ENDED 31ST DECEMBER, 2010

Parabolic Drugs Limited

Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh

Corporate Office: 9 AB, Taimoor Nagar, New Friends Colony, New Delhi

Unaudited Financial Results for the Quarter/Nine Months Ended 31st December, 2010

(Rs. Crores)

Particulars	Quarter ended 31/12/2010	Corresponding Quarter in the previous year ended 31/12/2009	Nine Months ended 31/12/2010	Corresponding Nine Months in the previous year ended 31/12/2009	Previous accounting Year ended 31/03/2010
	Unaudited	Audited	Unaudited	Audited	Audited
a) Gross Sales	164.46	122.93	466.04	374.52	559.01
Less : Excise Duty	(13.89)	(9.18)	(41.13)	(28.42)	(45.12)
Net Sales/Income from Operations	150.57	113.75	424.91	346.10	513.89
(b) Other Operating Income	0.89	2.98	1.80	4.05	4.87
1. Total Income	151.47	116.73	426.72	350.15	518.76
2. Expenditure					
a) (Increase)/Decrease in stock in trade and work in progress	(19.37)	(5.82)	(82.53)	(42.05)	(52.06)
b) Consumption of Raw Materials	124.65	85.62	382.14	286.55	419.92
c) Employees Cost	4.22	3.28	11.68	10.29	13.90
d) Depreciation & Amortisations	4.37	2.48	13.08	7.39	10.07
e) Other Expenditure	10.36	9.77	28.39	29.35	44.68
f) Total	124.23	95.33	352.75	291.53	436.51
3. Profit from Operations before Other Income, Interest & Exceptional Items	27.24	21.40	73.97	58.62	82.25
4. Other Income					
5. Profit before Interest & Exceptional Items (3 + 4)	27.24	21.40	73.97	58.62	82.25
6. Interest	11.03	10.40	25.46	29.57	38.22
7. Profit after Interest but before Exceptional Items (5-6)	16.21	11.00	48.51	29.05	44.03
8. Exceptional Items	-	-	-	-	-
9. Profit (+)/Loss(-) from Ordinary Activities before tax (7 + 8)	16.21	11.00	48.51	29.05	44.03
10. Tax expenses	3.73	1.63	11.21	6.53	9.83
11. Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9 - 10)	12.48	9.37	37.30	22.52	34.20
12. Extra Ordinary Items					
13. Net Profit (+)/ Loss(-) for the period (11-12)	12.48	9.37	37.30	22.52	34.20
14. Paid-up equity share capital (Face Value of Rs. 10/- each)	61.89	36.85	61.89	36.85	37.25
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	121.37
16. Earnings Per Share (EPS)					
- Basic EPS before extraordinary Items for the period for the year to date and for the previous year (not to be annualised)	2.02	5.21	6.88	17.10	17.91
- Diluted EPS before extraordinary Items for the period for the year to date and for the previous year (not to be annualised)	2.02	5.21	6.88	17.10	17.91
- Basic EPS after Extraordinary Items for the period, for the year to date and for the previous year (not to be annualised)	2.02	5.21	6.88	17.10	17.91
- Diluted EPS after Extraordinary Items for the period, for the year to date and for the previous year (not to be annualised)	2.02	5.21	6.88	17.10	17.91
17. Public Shareholding :					



- Number of Shares	38346994	13304706	38346994	13304706	13706029
- Percentage of Shareholding	61.96	36.11	61.96	36.11	36.79
18. Promoters and Promoter Group Shareholding (non-encumbered) :					
- Number of shares	23545020	23545020	23545020	23545020	23545020
- Percentage of shares (as a % of the to total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
- Percentage of shares (as a % of the to total share capital of the Company)	38.04	63.89	38.04	63.89	63.21

Notes :

1. The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 1st February ,2011 and Limited Review, as required under Clause 41 of the Listing Agreement, are subject to review by the Statutory Auditors.
2. During the period the Company has filed four Drug Master Files (DMF) with USFDA , two Certificate of Suitability (COS) with EDQM and four Process Patents for Non-Beta Lactum Products with Indian Patent Office.
3. There were no investor complaints pending at the beginning of the quarter. Four complaints received from the shareholders during the quarter has been disposed off. No investor complaint was pending at the end of the quarter.
4. The above financial results are on stand alone basis.
5. Figures of the previous year have been rearranged/regrouped wherever necessary.

Place : Derabassi
Date : 1st February, 2011

